JP2019504119A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504119A5 JP2019504119A5 JP2018553861A JP2018553861A JP2019504119A5 JP 2019504119 A5 JP2019504119 A5 JP 2019504119A5 JP 2018553861 A JP2018553861 A JP 2018553861A JP 2018553861 A JP2018553861 A JP 2018553861A JP 2019504119 A5 JP2019504119 A5 JP 2019504119A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- acy
- empty
- acylated
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 87
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 55
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 50
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 49
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 46
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 45
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 44
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 44
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 44
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 41
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 39
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 34
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 33
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 32
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 26
- 239000004471 Glycine Substances 0.000 claims 23
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 23
- 239000004474 valine Substances 0.000 claims 23
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 22
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 22
- 235000004279 alanine Nutrition 0.000 claims 22
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 22
- 229960000310 isoleucine Drugs 0.000 claims 22
- 239000004472 Lysine Substances 0.000 claims 20
- 239000004475 Arginine Substances 0.000 claims 19
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 19
- 235000009582 asparagine Nutrition 0.000 claims 19
- 229960001230 asparagine Drugs 0.000 claims 19
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 19
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 18
- -1 B 7 is Chemical compound 0.000 claims 15
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 15
- 239000000556 agonist Substances 0.000 claims 15
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 14
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 14
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 13
- 239000004473 Threonine Substances 0.000 claims 13
- 150000001413 amino acids Chemical class 0.000 claims 13
- 239000005557 antagonist Substances 0.000 claims 13
- 235000003704 aspartic acid Nutrition 0.000 claims 13
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 13
- 235000013922 glutamic acid Nutrition 0.000 claims 13
- 239000004220 glutamic acid Substances 0.000 claims 13
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 10
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 8
- 229940024606 amino acid Drugs 0.000 claims 7
- 235000001014 amino acid Nutrition 0.000 claims 7
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 7
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 6
- 230000002483 superagonistic effect Effects 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 5
- 101800004616 Adrenomedullin Proteins 0.000 claims 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 4
- 210000004900 c-terminal fragment Anatomy 0.000 claims 4
- 210000004898 n-terminal fragment Anatomy 0.000 claims 4
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims 3
- 108010033276 Peptide Fragments Proteins 0.000 claims 3
- 102000007079 Peptide Fragments Human genes 0.000 claims 3
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 claims 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 102000004379 Adrenomedullin Human genes 0.000 claims 2
- 101000584590 Homo sapiens Receptor activity-modifying protein 2 Proteins 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 2
- 102100030696 Receptor activity-modifying protein 2 Human genes 0.000 claims 2
- 230000010933 acylation Effects 0.000 claims 2
- 238000005917 acylation reaction Methods 0.000 claims 2
- 150000001408 amides Chemical group 0.000 claims 2
- 150000001507 asparagine derivatives Chemical class 0.000 claims 2
- 150000001510 aspartic acids Chemical class 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 150000002308 glutamine derivatives Chemical class 0.000 claims 2
- 150000002333 glycines Chemical class 0.000 claims 2
- SFVVQRJOGUKCEG-UHFFFAOYSA-N isoechinatine Natural products C1CC(O)C2C(COC(=O)C(O)(C(C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-UHFFFAOYSA-N 0.000 claims 2
- 150000002519 isoleucine derivatives Chemical class 0.000 claims 2
- 150000002614 leucines Chemical class 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 150000002994 phenylalanines Chemical class 0.000 claims 2
- 150000003354 serine derivatives Chemical class 0.000 claims 2
- 150000003668 tyrosines Chemical class 0.000 claims 2
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 101000690940 Homo sapiens Pro-adrenomedullin Proteins 0.000 claims 1
- 101000584583 Homo sapiens Receptor activity-modifying protein 1 Proteins 0.000 claims 1
- 102100030697 Receptor activity-modifying protein 1 Human genes 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 102000046663 human ADM Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000003679 valine derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662274638P | 2016-01-04 | 2016-01-04 | |
| US62/274,638 | 2016-01-04 | ||
| PCT/US2017/012171 WO2017120220A1 (en) | 2016-01-04 | 2017-01-04 | Peptide analogs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504119A JP2019504119A (ja) | 2019-02-14 |
| JP2019504119A5 true JP2019504119A5 (enExample) | 2020-01-09 |
| JP7360794B2 JP7360794B2 (ja) | 2023-10-13 |
Family
ID=59274070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553861A Active JP7360794B2 (ja) | 2016-01-04 | 2017-01-04 | ペプチド類似体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11034745B2 (enExample) |
| EP (1) | EP3400237A4 (enExample) |
| JP (1) | JP7360794B2 (enExample) |
| CN (2) | CN109311959A (enExample) |
| TW (1) | TW201734035A (enExample) |
| WO (1) | WO2017120220A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018362018A1 (en) * | 2017-11-06 | 2020-06-25 | Auckland Uniservices Limited | Peptide conjugate CGRP receptor antagonists and methods of preparation and uses thereof |
| EP3893895A4 (en) * | 2018-12-12 | 2022-11-23 | The Regents of University of California | Netrin-1 compounds and compositions thereof for treating pulmonary hypertension |
| CN114686427B (zh) * | 2022-05-23 | 2022-07-29 | 中国人民解放军总医院第一医学中心 | 一种脾脏调节型b淋巴细胞及其制备方法与应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| WO1996029432A1 (en) | 1995-03-22 | 1996-09-26 | Trustees Of Boston University | Methods for the detection of paracoccidioides |
| US6440421B1 (en) | 1996-04-18 | 2002-08-27 | Auchkland Uniservices Limited | Treatment of bone disorders with adrenomedullin or adrenomedullin agonists |
| IL118003A0 (en) | 1996-04-23 | 1996-08-04 | Yeda Res & Dev | Novel vip fragments and pharmaceutical compositions comprising them |
| US6268474B1 (en) | 1998-04-30 | 2001-07-31 | Creighton University | Peptide antagonists of CGRP-receptor superfamily and methods of use |
| US20090175821A1 (en) | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
| WO2004048547A2 (en) * | 2002-11-26 | 2004-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Intermedin and its uses |
| US20080026995A1 (en) | 2003-07-25 | 2008-01-31 | Ac Immune Sa | Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
| JP2008500281A (ja) | 2004-02-11 | 2008-01-10 | アミリン・ファーマシューティカルズ，インコーポレイテッド | アミリンファミリーペプチドおよびそれらを作成し使用するための方法 |
| US8076288B2 (en) * | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| JP2008507280A (ja) | 2004-07-21 | 2008-03-13 | アンブレツクス・インコーポレイテツド | 非天然コードアミノ酸を用いた生合成ポリペプチド |
| ZA200700359B (en) | 2004-07-21 | 2008-12-31 | Ambrx Inc | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| CA2580991A1 (en) | 2004-10-08 | 2006-04-20 | Amylin Pharmaceuticals, Inc. | Amylin family polypeptide-6 (afp-6) analogs and methods of making and using them |
| TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
| EP2390264A1 (en) | 2005-02-11 | 2011-11-30 | Amylin Pharmaceuticals Inc. | GIP analog and hybrid polypeptides with selectable propperties |
| MX2008002028A (es) | 2005-08-11 | 2008-03-27 | Amylin Pharmaceuticals Inc | Polipeptidos hibridos con propiedades de seleccion. |
| US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| WO2007109354A2 (en) | 2006-03-21 | 2007-09-27 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
| US8497240B2 (en) * | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| EP2059529A2 (en) | 2006-08-22 | 2009-05-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Screening method for gpcr ligands |
| CN104193815A (zh) | 2006-09-08 | 2014-12-10 | Ambrx公司 | 经修饰的人类血浆多肽或Fc骨架和其用途 |
| US7956035B2 (en) | 2007-03-01 | 2011-06-07 | Csl Limited | Treatment of endothelial dysfunction in diabetic patients |
| HRP20130920T1 (hr) | 2007-05-15 | 2013-11-08 | Otsuka Pharmaceutical Co., Ltd. | Postupak uporabe antagonista vazopresina s kemoterapijom antraciklina radi snižavanja kardiotoksiäśnosti i/ili poboljšanja stope preživljavanja |
| US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| AU2011204557B2 (en) * | 2010-01-08 | 2014-08-28 | Mallinckrodt Pharma Ip Trading D.A.C. | Fibrinogen preparations enriched in fibrinogen with an extended alpha chain |
| WO2012051324A1 (en) * | 2010-10-12 | 2012-04-19 | Alliance For Sustainable Energy, Llc | High bandgap iii-v alloys for high efficiency optoelectronics |
| EP2696884B1 (en) * | 2011-04-07 | 2019-04-03 | The Board of Trustees of the Leland Stanford Junior University | Long-acting peptide analogs |
| CA2861392C (en) * | 2012-01-26 | 2021-08-17 | Christopher J. Soares | Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use |
| WO2017139154A1 (en) * | 2016-02-09 | 2017-08-17 | Adepthera Llc | Dosing and use of long-acting clr/ramp agonists |
-
2017
- 2017-01-04 TW TW106100180A patent/TW201734035A/zh unknown
- 2017-01-04 US US16/066,609 patent/US11034745B2/en active Active
- 2017-01-04 CN CN201780015231.1A patent/CN109311959A/zh active Pending
- 2017-01-04 WO PCT/US2017/012171 patent/WO2017120220A1/en not_active Ceased
- 2017-01-04 EP EP17736247.2A patent/EP3400237A4/en active Pending
- 2017-01-04 JP JP2018553861A patent/JP7360794B2/ja active Active
- 2017-01-04 CN CN202310002994.XA patent/CN116063580A/zh active Pending
-
2021
- 2021-05-10 US US17/316,153 patent/US20220340633A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105616A1 (es) | Proteínas de fusión | |
| CN100506844C (zh) | 新的肽 | |
| ES2528599T3 (es) | Análogos truncados de un polipéptido insulinotrópico dependiente de glucosa | |
| RU2015110250A (ru) | ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ | |
| IL262805B2 (en) | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death | |
| KR20150003910A (ko) | Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법 | |
| TWI777260B (zh) | 芋螺毒素(conotoxin)肽之修飾及用途 | |
| CN102458438A (zh) | 具有肽骨架和c-末端修饰的经修饰补体抑素 | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| MX2020010806A (es) | Peptidos anti-inflamatorios y usos de los mismos. | |
| RU2017144098A (ru) | Гетеродимеризованный полипептид | |
| JP2019504119A5 (enExample) | ||
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| WO2021037942A1 (en) | Compstatin analogues and their medical uses | |
| JP2016516734A5 (enExample) | ||
| WO2012174397A3 (en) | Anti-inflammatory pharmaceutical products | |
| WO2017202394A1 (zh) | 用于防治阿尔茨海默病的融合蛋白及其制备方法和应用 | |
| JP7134093B2 (ja) | ペグ化バイオアクティブペプチド及びその使用 | |
| US20230100941A1 (en) | Molecules targeting mutant ras protein | |
| EP2388012A1 (en) | Kisspeptin peptides for use in the treatment of Alzheimer's disease, Creutzfeldt-Jakob disease or diabetes mellitus | |
| HRP20190544T1 (hr) | Ciklični analozi apelina | |
| JP2003500334A (ja) | 抗ｈｉｖ作用を有するｒａｎｔｅｓ由来ペプチド | |
| AU2005230886A1 (en) | Prokineticin 2beta peptide and its use | |
| CN105330735B (zh) | 一种prrt2蛋白相关的抗原表位肽及其应用 | |
| AU671118B2 (en) | Tachykinin antagonist tricyclic compounds, preparation of same and pharmaceutical compositions containing such compounds |